Mazumdar, Abhijit
Tahaney, William M. http://orcid.org/0000-0002-7302-3161
Reddy Bollu, Lakshmi
Poage, Graham http://orcid.org/0000-0003-1270-6396
Hill, Jamal
Zhang, Yun
Mills, Gordon B.
Brown, Powel H.
Funding for this research was provided by:
Susan G. Komen for the Cure, Komen Wyoming Affiliate (KG081694)
Susan G. Komen (9SAB12-00006, KG081694, SAC110052)
Division of Cancer Prevention, National Cancer Institute (P30 CA016672)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA016672)
Article History
Received: 12 October 2018
Accepted: 26 June 2019
First Online: 26 July 2019
Competing interests
: P.H.B. served as a Scientific Advisory Board Member for the Susan G. Komen for the Cure Foundation (until 2017), and P.H.B. is a holder of GeneTex stock (<1% of the total company stock); neither of these relate to this publication. G.B.M. serves as a Consultant/Scientific Advisory Board Member for AstraZeneca, Catena Pharmaceuticals, Critical Outcome Technologies, ImmunoMET, Ionis, Signalchem Lifesciences, Symphogen, Takeda/Millenium Pharmaceuticals, and Tarveda. G.B.M. is a holder of stock/options/financial companies for Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindletop Ventures, and Tarveda. G.B.M. has licensed the HRD assay to Myriad Genetics and has intellectual property on the Nanostring DSP platform. G.B.M. is sponsored by the following research companies: Adelson Medical Research Foundation, AstraZeneca, Breast Cancer Research Foundation, Immunomet, Ionis, Karus Therapeutics, Komen Research Foundation, Nanostring, Ovarian Cancer Research Foundation, Pfizer, Prospect Creek Foundation, and Takeda/Millenium Pharmaceuticals. None of these relate to this publication (G.B.M.). All remaining authors declare no actual, potential, or perceived conflict of interest that would prejudice the impartiality of this article.